AstraZeneca PLC (AZN)vsIntelligent Bio Solutions Inc. (INBS)
AZN
AstraZeneca PLC
$185.67
+3.13%
HEALTHCARE · Cap: $286.37B
INBS
Intelligent Bio Solutions Inc.
$2.44
-3.94%
HEALTHCARE · Cap: $6.77M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1544351% more annual revenue ($60.44B vs $3.91M). AZN leads profitability with a 17.2% profit margin vs -296.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
INBS
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.8%
Fair Value
$194.77
Current Price
$185.67
$9.10 discount
Margin of Safety
-23.2%
Fair Value
$4.26
Current Price
$2.44
$1.82 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while INBS is a hypergrowth play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.24 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 38/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology firm specializing in the development of advanced diagnostic solutions and biomarker-driven technologies for drug abuse testing and monitoring. The company's innovative approach harnesses state-of-the-art scientific methodologies to deliver rapid and accurate testing options, enabling timely clinical decision-making and enhancing patient outcomes. As the demand for sophisticated diagnostic tools continues to rise, INBS is strategically positioned to lead the transformation of healthcare diagnostics, underscoring its commitment to improving healthcare quality and efficiency.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?